This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bal, CS, A Kumar, and GS Pant. 2004. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89(4):1666–1673.
Bal, C, AK Padhy, S Jana, GS Pant, and AK Basu. 1996. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574–2580.
Barbaro, D, G Boni, G Meucci, U Simi, P Lapi, P Orsini, C Pasquini, F Piazza, M Caciagli, and G Mariani. 2003. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88(9):4110–4115.
Chow, SM, SC Law, WM Mendenhall, SK Au, PT Chan, TW Leung, CC Tong, IS Wong, and WH Lau. 2002. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52(3):784–795.
Chow, SM, SC Law, WM Mendenhall, SK Au, S Yau, O Mang, and WH Lau. 2004. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 42(2):176–183.
Doi, SA, and NJ Woodhouse. 2000. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxford) 52(6):765–773.
Jarzab, B, JD Handkiewicz, J Wloch, B Kalemba, J Roskosz, A Kukulska, and Z Puch. 2000. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 27(7):833–841.
Lopez-Penabad, L, AC Chiu, AO Hoff, P Schultz, S Gaztambide, NG Ordonez, and SI Sherman. 2003. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97:1186–1194.
Maxon, HR, EE Englaro, SR Thomas, VS Hertzberg, JD Hinnefeld, LS Chen, H Smith, D Cummings, and MD Aden. 1992. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33:1132–1136.
Mazzaferri, EL. 1997. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7(2):265–271.
Mazzaferri, EL, and RT Kloos. 2001. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86(4):1447–1463.
Sawka, AM, K Thephamongkhol, M Brouwers, L Thabane, G Browman, and HC Gerstein. 2004. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89(8):3668–3676.
Sugg, SL, S Ezzat, IB Rosen, JL Freeman, and SL Asa. 1998. Distinctmultiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83:4116–4122.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Amdur, R.J., Mazzaferri, E.L. (2005). I-131 Therapy in a Patient with a Small Thyroid Remnant. In: Amdur, R.J., Mazzaferri, E.L. (eds) Essentials of Thyroid Cancer Management. Springer, Boston, MA. https://doi.org/10.1007/0-387-25714-4_32
Download citation
DOI: https://doi.org/10.1007/0-387-25714-4_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25713-6
Online ISBN: 978-0-387-25714-3
eBook Packages: MedicineMedicine (R0)